| 奚晓雪,陈婷,侯顺玉,等.子宫内膜异位症病人卵巢储备功能与维生素 D的关系研究[J].安徽医药,2021,25(10):1985-1989. |
| 子宫内膜异位症病人卵巢储备功能与维生素 D的关系研究 |
| Relationship between circulating anti-mullerian hormone status and the level of serum vitamin D in women with endometriosis |
| |
| DOI：10.3969/j.issn.1009-6469.2021.10.018 |
| 中文关键词: 子宫内膜异位症 卵巢储备功能 抗苗勒管激素 维生素 D 卵巢囊肿 |
| 英文关键词: Endometriosis Ovarian reserve Anti-mullerian hormone Vitamin D Cyst |
| 基金项目:苏州市科技计划 -关键技术应用研究( ss201873)；南京医科大学科技发展基金( NMUB2019334) |
|
| 摘要点击次数: 1077 |
| 全文下载次数: 457 |
| 中文摘要: |
| 目的探究子宫内膜异位症病人血清维生素 D(VD)及抗苗勒管激素(AMH)水平变化及其相关性。方法选取 2019年 9 —11月苏州市立医院收治的卵巢良性肿瘤病人 109例，入院时测定血清 VD及 AMH水平，根据术后病理，其中 49例卵巢子宫内膜异位症为巧囊组，其他类型卵巢肿瘤 60例为对照组，对比两组 VD及 AMH水平并分析其相关性。使用随机数字表法将巧囊组分为 VD组和安慰剂组，分别于 VD及安慰剂治疗前和治疗 3个月后检测两组血清 VD和 AMH水平。结果巧囊组病人 AMH水平(3.39±0.34)μg/L低于对照组( 3.61±0.43)μg/L，巧囊组病人和对照组相比， VD水平偏低( 12.90±1.14)μg/L比( 13.74±1.39)μg/L(P<0.05)。巧囊组病人血清 VD与 AMH存在弱的正相关性(Pearson’s r=0.345，P=0.015)；而对照组病人两者无相关性(Pearson’s r=0.087，P=0.646)。VD组和安慰剂组术后 3d血清 AMH下降比率(%)分别为 19.43和 20.47。VD组在治疗 3月后血清 AMH值明显高于安慰剂组(P=0.029)。VD组和安慰剂组术后 3月血清 AMH恢复比率分别为 30.26%和 23.98%。结论卵巢子宫内膜异位症相对其他良性卵巢肿瘤病人，血清 VD及 AMH水平较低，且两者存在弱相关性。卵巢子宫内膜异位症术后使用 VD治疗， AMH恢复较快。 VD有潜力作为一种辅助疗法改善卵巢子宫内膜异位症卵巢储备功能。 |
| 英文摘要: |
| Objective To evaluate the level and relationship of serum vitamin D (VD) and anti-Mullerian hormone (AMH) levels in patients with endometriosis.Methods One hundred and nine patients with benign ovarian cysts who admitted to Suzhou MunicipalHospital from September to November 2019 were selected. Serum VD and AMH levels were measured upon admission. According topostoperative pathology, 49 patients with endometriotic cysts were selected as endometriosis group, 60 patients with other benign cystswere selected as control group. The levels of VD and AMH between the two groups were compared and their correlations were analyzed.The endometriosis group was randomly divided into VD group and placebo group by using simple random sampling. Serum VD andAMH levels were detected before placebo treatment and after treatment of three months.Results The serum AMH level in endometriosis group (3.39±0.34)μg/L was significantly lower than that in the control group (3.61±0.43)μg/L,P<0.05. The level of VD in endometriosis group was lower than that in control group (12.90±1.14)μg/L vs. (13.74±1.39)μg/L,P<0.05. There was a weak correlation between VD and AMH in endometriosis group by global analysis (Pearson's r=0.345, P=0.015), while there was no correlation in control group (Pearson's r=0.087, P=0.646). The reduction rate of serum AMH (%) in the VD group and the placebo group was19.43 and 20.47, respectively, at 3 days after operation. After three months of VD treatment, serum AMH levels in VD group were significantly higher thanthose in placebo group (P= 0.029). The recovery rate of serum AMH in VD group and placebo group was 30.26 and 23.98, respectively,at 3 days after operation. The serum AMH level in VD group recovered to 30.26% after 3 months, while that in placebo group was only23.98%.Conclusions Compared with control group, endometriosis patients has lower serum VD and AMH levels, and there is a weakcorrelation between VD and AMH. The AMH level of endometriosis patients recovers quickly after the treatment of VD. VD has the potential as an adjuvant therapy to improve ovarian reserve in ovarian endometriosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
